CD4 and neoplasm: While patients who received mFFX had decreased infiltration by the CD4 T cell aggregate compared to the Gem-based group, there were no statistical differences in immune infiltration by the individual CD4 T cell phenotypes included in the aggregate (Supplementary Table 1), suggesting a similar initial immune cell phenotypic infiltration between treatment groups.Chemotherapy response was associated with variations in expression of tumor pre-treatment immunomodulating genes (Figures 3A, B).